Deka Biosciences Inc. has submitted an IND application to the FDA for its lead oncology asset, DK2-10 (EGFR). DK2-10 (EGFR) is the first of many experimental therapeutics developed as part of Deka’s platform of molecules, with each Diakine in Deka's platform consisting of two complementary cytokines coupled together via attachment to a single chain variable fragment, enabling the cytokines to accumulate more specifically in targeted tissues.
Metabolic health is at an odd juncture. With the advent of glucagon-like peptide (GLP-1) agonists, pharmacologically induced weight loss has matured into a viable therapeutic option at long last. And research into the drug class is continuing apace.
Mindrank Ltd. has received clearance of its IND application by the FDA for MDR-001, a small-molecule glucagon-like peptide 1 (GLP-1) receptor agonist, which was discovered using the company’s proprietary artificial intelligence (AI) platform, Molecule Pro.
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has developed antibody-drug conjugates (ADCs) consisting of 19F6_Hu35V1 antibody covalently linked to a cytotoxic drug through a linker.
Research at Silexon Biotech Co. Ltd. has led to the identification of mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer, hepatitis B virus, hepatitis C virus and HIV infections.
Several recent patents from Vertex Pharmaceuticals Inc. have disclosed sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain, arrhythmia, Charcot-Marie-tooth disease, cough, urinary incontinence and multiple sclerosis.
An Otsuka Pharmaceutical Co. Ltd. patent describes pyrazolo[1,5-a]pyrimidine lysophosphatidic acid receptor 2 (LPAR2; EDG4) antagonists reported to be useful for the treatment of atopic dermatitis, psoriasis, eczema, scleroderma and pruritus, among others.
Trastuzumab deruxtecan (DS-8201a) is an antibody-drug conjugate used for the treatment of metastatic HER2+ breast cancer that is refractory to anti-HER2 therapy such as T-DM1, however, there is a lack of knowledge on acquired or innate resistance to the drug.
Researchers from Kbluebio Inc. and affiliated organizations recently reported the discovery and preclinical evaluation of a novel prohibitin-2 (PHB2) ligand as a potential candidate for the treatment of multiple myeloma (MM).
RSS
